Supplementary Figures

Oncogenic VEGFR2 rewires the extracellular matrix to impair endothelial mechanics and destabilize tumor vasculature

Authors

Mattia Domenichini[1,2*], Michela Corsini[1,2*], Cosetta Ravelli[1,2], Anastasia Ricci[5], Elisa Moreschi[1], Elisabetta Grillo[1,2], Camilla Maggi[1], Gianluca Baldanzi[3], Sonia Chiodini[1,4], Diana Eveline Sanchez-Amador[4], Julia Kraxner[5], Michael G. Monaghan[4], Holger Gerhardt[5], Michele Menotta[6] and Stefania Mitola[1,2#]

Affiliations

[1]Department of Molecular and Translational Medicine, Università degli Studi di Brescia, Via Branze 39, Brescia, Italy

[2] Mechanobiology Research Center at UNIBS, Università degli Studi di Brescia, Italy


[3] Center for Translational Research on Allergic and Autoimmune Diseases, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

[4] Discipline of Mechanical, Manufacturing and Biomedical Engineering, School of Engineering, Trinity College Dublin, Dublin 2, Ireland.

[5]Integrative Vascular Biology, Max Delbrück Center (MDC), Robert-Rössle-Straße 10, Berlin, Germany


[6]Department of Biomolecular Sciences University of Urbino "Carlo Bo", Via Saffi 2 61029 Urbino (PU) ITALY

Supplementary Figure 1.



Supplementary Figure 1. CD31 (white), Vimentin (red) staining and merge channels of VEGFR2^{WT} and VEGFR2^{R1032Q} Sk-Mel-31-derived tumors, scale bar 10µm. White arrows indicate Vimentin signal in endothelial cells

Supplementary Figure 2.



Supplementary Figure 2. Representative images of CD31 (red), α-SMA (green), and TO-PRO-3 (gray) staining in VEGFR2^{WT}- and VEGFR2^{R1032Q} Sk-Mel-31-derived tumors, scale bar 10 µm. Merged channels show α-SMA-positive perivascular coverage of CD31-positive tumor vessels.